Method Sign up free

Borrower record · Q2 2026

Heron Therapeutics

As filed by Hercules Capital, Inc. · period end 30 June 2026No sector — one filer, nothing to corroborate

Hercules Capital, Inc. is the only BDC lending to Heron Therapeutics: $78.5m across two positions at Q2 2026, marked at 97.0 cents. One of the two positions pays interest in kind, at 100bp.

Filed fair value
$78.5m
2 funded positions
Aggregate mark
97.0c
cost filed on all 2 positions
Filed spread
195bp
over Prime, one floating tranche
Maturities to
2030
one date, 1 September 2030
Periods on record
5
Q2 2025 → Q2 2026

How this total is counted

Capital structure

First-Lien Senior Secured1 position
$78.5m
>99.9%
Equity/Other1 position
$4k
<0.1%

All 2 funded positions carry a filed seniority.

Rate structure

Floating, on the one position whose interest type a filer disclosed.

1 of 2 funded positions carries no filed interest type.

Maturity profile

1 of 2 funded positions dated
2030
$78.5m

4.2 years to maturity, weighted by fair value across the 1 dated position.

Filed over time

5 periods · aggregate only

Filed fair value

$22.6m
Q2 2025
$80.0m
Q3 2025
$80.4m
Q4 2025
$79.2m
Q1 2026
$78.5m
Q2 2026

Aggregate marknot to zero

104.7c
Q2 2025
99.8c
Q3 2025
99.8c
Q4 2025
98.3c
Q1 2026
97.0c
Q2 2026

Q2 2025, Q3 2025, Q4 2025, Q1 2026, Q2 2026 — every filer reporting the borrower at each period, aggregated. No lender is separated out at any period.

Credit flags

Pays in kind1 position at 1 lender carry a PIK component, the largest filed at 100bp, $78.5m of fair value.

Not in the filings

Sign up for free

Tell me when this changes.

One lender reports Heron Therapeutics today. We will email you when a second one does, when Hercules Capital, Inc.'s mark moves, or when the position leaves the schedule.

Every filing behind this page

1 filer · Q2 2026
FilerCIKFormPeriodFiledAccession
Hercules Capital, Inc. (HTGC)000128078410-Q2026-06-302026-07-300001280784-26-000042

Related borrowers

Same lender